GURUFOCUS.COM » STOCK LIST » USA » NYSE » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » EV-to-EBITDA
Switch to:

Bristol-Myers Squibb Co EV-to-EBITDA

: 9.63 (As of Today)
View and export this data going back to 1952. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bristol-Myers Squibb Co's enterprise value is $187,070 Mil. Bristol-Myers Squibb Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was $19,423 Mil. Therefore, Bristol-Myers Squibb Co's EV-to-EBITDA for today is 9.63.

The historical rank and industry rank for Bristol-Myers Squibb Co's EV-to-EBITDA or its related term are showing as below:

BMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.28   Med: 18.68   Max: 57.3
Current: 9.76

During the past 13 years, the highest EV-to-EBITDA of Bristol-Myers Squibb Co was 57.30. The lowest was 6.28. And the median was 18.68.

BMY's EV-to-EBITDA is ranked better than
65.13% of 717 companies
in the Drug Manufacturers industry
Industry Median: 12.97 vs BMY: 9.76

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2022-08-09), Bristol-Myers Squibb Co's stock price is $74.9554. Bristol-Myers Squibb Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $3.010. Therefore, Bristol-Myers Squibb Co's PE Ratio for today is 24.90.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Bristol-Myers Squibb Co EV-to-EBITDA Historical Data

The historical data trend for Bristol-Myers Squibb Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.49 12.24 23.76 35.11 8.09

Bristol-Myers Squibb Co Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.61 20.30 8.09 9.72 10.00

Competitive Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Bristol-Myers Squibb Co EV-to-EBITDA Distribution

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's EV-to-EBITDA falls into.



Bristol-Myers Squibb Co EV-to-EBITDA Calculation

Bristol-Myers Squibb Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=187069.572/19423
=9.63

Bristol-Myers Squibb Co's current Enterprise Value is $187,070 Mil.
Bristol-Myers Squibb Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $19,423 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bristol-Myers Squibb Co  (NYSE:BMY) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Bristol-Myers Squibb Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=74.9554/3.010
=24.90

Bristol-Myers Squibb Co's share price for today is $74.9554.
Bristol-Myers Squibb Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.010.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Bristol-Myers Squibb Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Bristol-Myers Squibb Co Business Description

Bristol-Myers Squibb Co logo
Address
430 East 29th Street, 14th Floor, New York, NY, USA, 10016
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Executives
Greenlees Sharon officer: SVP & Controller BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Shanahan Karin officer: EVP, Glob. Prod. Dev. & Supply BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Meyers Gregory Scott officer: EVP, Chief Digital & Tech Off. BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Weese Michelle officer: EVP, Corporate Affairs BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Hidalgo Medina Manuel director BRISTOL MYERS SQUIBB 430 E. 29TH STREET, 14TH FLOOR NEW YORK NY 10016
Rice Derica W director 1000 NICOLLET MALL TPS-3155 MINNEAPOLIS MN 55403
Price Paula A director ONE CVS DRIVE WOONSOCKET RI 02895
Mily Elizabeth officer: EVP, Strategy & BD BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVENCE LINE ROAD PRINCETON NJ 08540
Metcalfe Kathryn officer: EVP, Corporate Affairs BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Vessey Rupert officer: Pres., Research & Early Dev. C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Elkins David V officer: EVP, Chief Financial Officer C/O BECTON, DICKINSON AND COMPANY 1 BECTON DRIVE FRANKLIN LAKES NJ 07417
Bonney Michael W director 65 HAYDEN AVE LEXINGTON MA 02421
Yale Phyllis R director
Ahmed Nadim officer: President, Hematology C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Haller Julia A director C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901

Bristol-Myers Squibb Co Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)